MENU

2020

 

 

Medicine/s Name Dosage/s and Strength/s Remarks Issuance
Zidovudine + Lamivudine 

•60 mg + 30 mg dispersible tablet

- Indication: (1) Treatment of Human Immunodeficiency Virus (HIV) infection in
children.

- Remarks: Additional pediatric formulation to the currently listed zidovudine 300 mg
+ lamivudine 150 mg

Department Memorandum no. 2020-0310
Nevirapine

•50 mg dispersible tablet

- Indication: Treatment of Human Immunodeficiency Virus (HIV) infection in children

- Remarks: Additional pediatric formulation to the currently listed nevirapine 200 mg
tablet and 50 mg/S mL. suspension, 240 mL.

Department Memorandum no. 2020-0310
Lopinavir + ritonavir

40 mg + 10 mg oral pellets contained in capsule

 

- Indication: Treatment of Human Immunodeficiency Virus (HIV) infection in
chuldren.

- Remarks: Additional pediatric formulation to the currently listed lopinavir + ritonavir
200 mg + 50 mg tablet/capsule.

Department Memorandum no. 2020-0310
Ipratropium (as bromide) + Salbutamol

•20 mcg + 100 mcg MDI

- Revised in the specifications

Department Memorandum no. 2020-0321
Pantoprazole

•20 mg and 40 mg tablet/enteric-coated tablet

 

- Indication: (1) Treatment of mild, moderate and severe reflux esophagitis, duodenal ulcer, gastric ulcer, Zollinger-Ellison-Syndrome, in combination with two appropriate antibiotics (for the eradication of H. pylori in patients with peptic ulcers with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism) in adults; (2) reflux esophagitis, symptomatic gastroesophageal reflux disease (GERD) in children 5- 17 years of age; (3) prevention of gastroduodenal ulcers induced by continuous nonsteroidal antiinflammatory drug (NSAID)
treatment; and (4) long-term management and prevention of "relapse in reflux esophagitis.

- Government list price:

PHP 27 per 20 mg tablet

PHP 14.50 per 40 mg tablet

Department Memorandum no. 2020-0018